Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal ...

Liver diseases, especially fatty liver, are rising fast, even among non-drinkers. Liver specialist Dr Saurabh Sethi shares 9 ...

Liver diseases, especially fatty liver, are rising fast, even among non-drinkers. Liver specialist Dr Saurabh Sethi shares 9 ...

Despite being the largest internal organ and a vital powerhouse of the body, the liver’s health is often overlooked. Dr.

Traditional cardiovascular risk assessment tools underperform among individuals with metabolic dysfunction-associated steatotic liver disease.

Introduction Liver cirrhosis and other chronic liver diseases is a serious public health problem, and its incidence, morbidity, and mortality have increased in recent years (1). In 2019, 1691.0 ...

A report into the timeliness of compensation for those infected and affected is due to be published on Wednesday, following ...

Adding bile acids as farnesoid X receptor agonists to the culture medium supported the growth and development of unique stem ...

Liver cirrhosis is a serious condition. It damages the liver over time. Common causes include alcohol, hepatitis, and fatty ...

Around 25% of our population has this condition, and results from a new study could help shape how it's treated.

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects nearly one in three adults around the globe. It ...

We wanted to find out if rifaximin could be used to prevent and treat hepatic encephalopathy in people with cirrhosis; whether it does this better than no drug treatment, a dummy pill (placebo), or ...